

To: [redacted] [redacted]@rivm.nl]; [redacted] [redacted]@rivm.nl]
From: [redacted] [redacted]
Sent: Wed 11/25/2020 5:03:07 PM
Subject: FW: HSC - COVID-19 testing
Received: Wed 11/25/2020 5:03:11 PM
[Overview table - RAT in Europe.docx](#)

Van: [redacted]@ec.europa.eu
Verzonden: woensdag 25 november 2020 18:03:01 (UTC+01:00) Amsterdam, Berlijn, Bern, Rome, Stockholm, Wenen
Aan: [redacted]@ec.europa.eu
Onderwerp: HSC - COVID-19 testing

Dear Members of the Health Security Committee,
Dear colleagues,

In preparation of the next HSC meeting this Friday, please find below two points related to COVID-19 testing.

1. Mutual recognition

Mutual recognition of COVID-19 test results among EU Member States is a prerequisite to facilitate cross border movement, contact tracing and treatment. This is true for RT-PCR tests, but also for the new generation of rapid antigen tests. The Commission Recommendation of 18 November states that "*Results performed with tests that have been validated at national level by one Member State and that meet the criteria of sensitivity and specificity of this Recommendation, should be recognised by other Member States.*"

As a follow-up, the Commission would like to request HSC Members' replies to the questions below:

1. Is mutual recognition of COVID-19 test results currently a problem in your country?
2. In which settings/situations are results of rapid antigen tests currently used and approved for public health measures?
3. Would your MS support a common position of the HSC on mutual recognition of RAT test results (e.g. specifying the situations in which such results should be mutually recognised)?

We would appreciate your responses to these questions by **Thursday 26 November COB** for further discussion at the HSC meeting the day after.

2. Overview table RAT

Attached you will find the latest version of the overview table on rapid antigen tests in Europe. Various updates were provided, which have been highlighted in yellow.

Kind regards,

HSC Secretariat